|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Bone Metastases - Impending Patent Expiries May Help Make or Break Newer Agents
Datamonitor, March 2008, Pages: 100
Bone metastases are a complication of some advanced cancers including cancers of the breast, lung, prostate, kidney and thyroid. The incidence of bone metastases across these tumor types in the seven major markets is forecasted to total 225,174 in 2008. While treatment with bisphosphonates reduces the risk of skeletal complications, they do not improve survival in the majority of patients.
Scope
- Overview of bone metastases epidemiology, which is currently unknown, disease mechanisms, complications and diagnosis
- Current treatment options and identification of unmet needs in bone metastases
- Research and analysis of the bone metastases pipeline with clinical and commercial assessment of late-phase candidates
- Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Highlights of this title
Current bisphosphonate therapy reduces the risk of skeletal complications such as fractures and bone pain but as yet do not offer a survival advantage in the majority of patients. More efficacious agents that improve survival and enhance the quality of life of advanced cancer patients with bone metastases would be highly welcome.
Survival of bone metastases patients varies according to primary cancer type and largely remains unchanged with current treatment. In light of this, an emerging opportunity is the potential of bisphosphonate therapy to prevent bone metastases when given in early stage cancer patients, for which trials are ongoing.
Approaching patent expiries for Bondronat and Zometa and the subsequent availability of cheaper generic versions may raise the barrier to uptake of more novel but costly emerging agents such as denosumab. However, significant opportunity exists to succeed in the bone metastases market if newer agents can demonstrate superior efficacy and/or safety.
Key reasons to purchase this title
- Gain an insight into the epidemiology trends as the true incidence of bone metastases is currently unknown
- Identify the limitations of current bone metastases therapy and consider the remaining unmet needs
- Acquire a detailed appreciation and impartial perspective of the bone metastases pipeline and identify the key products in late-phase development
Customers who bought this item also bought
Bisphosphonates Update - The Treatment and Prevention of Bone Metastases in Breast and Prostate Cancer
Bisphosphonates and Other Bone-Targeting Compounds in the Treatment of Cancer
Stakeholder Opinions: Brain Metastases - Turning Prolonged Survival on its Head?
Can Denosumab Achieve Superiority For The Prevention Of SREs In Cancer?
Brain metastases
Bone Graft Substitutes Clinical Trial Analysis
Bone Densitometers - Global Strategic Business Report
Bone Grafts - A US Market Analysis
Bone Grafts - A US Market Analysis
Dental Bone Graft Substitutes and Tissue Regeneration Materials Clinical Trial Analysis
Imaging Review: Body, Bone & Breast
Bone Repair Biomaterials
|
|
|
|
